AGIO

SEC source: 0001209191-18-059146 · doc4.xml · nonDerivative · entry 1

Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 270,772

F1 · kind: This disposition reflects a gift of 1,000 shares to a charitable trust.

F2 · ownership.nature: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.

SEC source: 0001209191-18-057556 · doc4.xml · derivative · entry 6

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,154

Underlying: Common stock · 3,000 shares

Expires 2023-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.

SEC source: 0001209191-18-057556 · doc4.xml · nonDerivative · entry 4

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,932

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-057556 · doc4.xml · nonDerivative · entry 3

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,032

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $70.00 to $70.57. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-057556 · doc4.xml · nonDerivative · entry 2

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,732

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.97 to $69.91. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-057556 · doc4.xml · nonDerivative · entry 1

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,932

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-054513 · doc4.xml · derivative · entry 7

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,154

Underlying: Common stock · 3,000 shares

Expires 2023-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.

SEC source: 0001209191-18-054513 · doc4.xml · nonDerivative · entry 5

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,932

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-054513 · doc4.xml · nonDerivative · entry 4

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,953

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $70.61 to $71.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-054513 · doc4.xml · nonDerivative · entry 3

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,053

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $69.24 to $70.22. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-054513 · doc4.xml · nonDerivative · entry 2

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,032

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.13 to $69.05. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-054513 · doc4.xml · nonDerivative · entry 1

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,932

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-19-011483 · doc4.xml · nonDerivative · entry 1

Alenson Carman · CIK 0001688865 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.44 to $76.47. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-050824 · doc4.xml · nonDerivative · entry 3

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,047

F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $71.70 to $72.17. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-057372 · doc4a.xml · nonDerivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,209

F1 · kind: On September 13, 2018, the reporting person filed a Form 4 reporting the sale of 14,162 shares of common stock. The previously reported transaction was subsequently broken and unwound by the broker and, therefore, did not in fact occur for the reporting person's account. As of September 12, 2018, the reporting person beneficially owned 36,209 shares of common stock of Agios Pharmaceuticals, Inc.

F1 · price: On September 13, 2018, the reporting person filed a Form 4 reporting the sale of 14,162 shares of common stock. The previously reported transaction was subsequently broken and unwound by the broker and, therefore, did not in fact occur for the reporting person's account. As of September 12, 2018, the reporting person beneficially owned 36,209 shares of common stock of Agios Pharmaceuticals, Inc.

SEC source: 0001209191-18-050824 · doc4.xml · nonDerivative · entry 2

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,209

F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $73.33 to $74.25. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-050824 · doc4.xml · nonDerivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,609

F1 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $72.27 to $72.89. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-050631 · doc4.xml · derivative · entry 4

Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,471

Underlying: Common stock · 8,730 shares

Expires 2024-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-18-050631 · doc4.xml · nonDerivative · entry 1

Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,849

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-050050 · doc4.xml · derivative · entry 3

Alenson Carman · CIK 0001688865 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,266

Underlying: Common stock · 312 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · derivative.exercise_date: This option was granted on November 7, 2016. The shares underlying this option vest as to 25% of the underlying shares on November 7, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-18-050050 · doc4.xml · nonDerivative · entry 2

Alenson Carman · CIK 0001688865 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152

F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-050050 · doc4.xml · nonDerivative · entry 1

Alenson Carman · CIK 0001688865 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 464

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · balance_after: Includes 152 shares purchased through the Company's employee stock purchase plan.

SEC source: 0001209191-18-050064 · doc4.xml · derivative · entry 6

Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,201

Underlying: Common stock · 2,500 shares

Expires 2024-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-18-050064 · doc4.xml · derivative · entry 5

Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 72,619 shares

Expires 2022-04-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on April 6, 2012 for the purchase of 72,727 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013, resulting in the vesting of the option as to 18,181 shares. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 36,364 shares, and the remaining 18,182 shares vested on April 4, 2015.

SEC source: 0001209191-18-050064 · doc4.xml · nonDerivative · entry 2

Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-050064 · doc4.xml · nonDerivative · entry 1

Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,619

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-050043 · doc4.xml · derivative · entry 5

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,154

Underlying: Common stock · 3,000 shares

Expires 2023-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.

SEC source: 0001209191-18-050043 · doc4.xml · nonDerivative · entry 4

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,196

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-050043 · doc4.xml · nonDerivative · entry 3

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,296

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $83.00 to $83.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-050043 · doc4.xml · nonDerivative · entry 2

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,556

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.00 to $82.98. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-050043 · doc4.xml · nonDerivative · entry 1

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,196

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-049065 · doc4.xml · derivative · entry 6

Bowden Christopher · CIK 0001608601 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common stock · 1,700 shares

Expires 2024-05-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-18-049065 · doc4.xml · nonDerivative · entry 4

Bowden Christopher · CIK 0001608601 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 924

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.00 to $80.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-049065 · doc4.xml · nonDerivative · entry 3

Bowden Christopher · CIK 0001608601 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,624

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-049065 · doc4.xml · derivative · entry 5

Bowden Christopher · CIK 0001608601 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,700

Underlying: Common stock · 300 shares

Expires 2024-05-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-18-049065 · doc4.xml · nonDerivative · entry 2

Bowden Christopher · CIK 0001608601 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 924

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-049065 · doc4.xml · nonDerivative · entry 1

Bowden Christopher · CIK 0001608601 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,224

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-048672 · doc4.xml · derivative · entry 3

Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,650

Underlying: Common stock · 2,050 shares

Expires 2026-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-18-048672 · doc4.xml · nonDerivative · entry 2

Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-048672 · doc4.xml · nonDerivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,050

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-045820 · doc4.xml · derivative · entry 5

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,154

Underlying: Common stock · 3,000 shares

Expires 2023-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.

SEC source: 0001209191-18-045820 · doc4.xml · nonDerivative · entry 4

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,196

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.64 to $81.01. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-045820 · doc4.xml · nonDerivative · entry 3

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,796

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.53 to $80.45. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-045820 · doc4.xml · nonDerivative · entry 2

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,896

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.01 to $78.53. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-18-045820 · doc4.xml · nonDerivative · entry 1

Biller Scott · CIK 0001581956 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,196

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-044183 · doc4.xml · derivative · entry 3

Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,700

Underlying: Common stock · 2,050 shares

Expires 2026-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-18-044183 · doc4.xml · nonDerivative · entry 2

Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-044183 · doc4.xml · nonDerivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,050

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-18-043734 · doc4.xml · derivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The performance share units were originally granted on February 16, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F2 · derivative.expiration_date: The performance share units were originally granted on February 16, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

SEC source: 0001209191-18-043731 · doc4.xml · derivative · entry 1

Hirsch Andrew · CIK 0001586707 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F2 · derivative.expiration_date: The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.